Royalty Pharma delivered robust 2025 results, with Q4 receipts up 17% to $856 million and full-year portfolio receipts at $3.25 billion. The company deployed $2.6 billion into 9 new royalties and ...
Ligand Pharmaceuticals delivered an upbeat earnings call that balanced robust current performance with an ambitious expansion plan. Management highlighted strong royalty growth, rising adjusted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results